Skip to Content
Søg Menu

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

Anne Stidsholt Roug, Consultant, Ph.D, Department of Hematology, Aarhus University Hospital & Clinical Lecturer, Hematology Department, Aalborg University Hospital, presented highlights and Danish perspectives on AML at the Danish Evening at EHA 2024.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Hans Beier Ommen

ASH 2024: Nyt om AML i dansk perspektiv

/ Hans Beier Ommen
ASH24AML Play the Video 09:10
Bjørn Tore Gjertsen

ASH 2024: AML-forskning tar nye steg med CPX-behandling og meninhemmere

/ Bjørn Tore Gjertsen
ASH24AML Play the Video 04:15
Gunnar Juliusson

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Gunnar Juliusson
AML Play the Video 07:05
Hanna Duàn

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hanna Duàn
ASH24AML Play the Video 2:36
Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

/ BestPractice Nordic
EHA24CLL

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top